



## Brown University Health - Institutional Biosafety Committee Minutes

October 6, 2025 Videoconference

Present: Dr. Jayasuriya, (Chairperson), Dr. Dubielecka-Szczerba (Vice Chairperson), Dr. Gregory,  
Mr. McEvoy, Dr. Merley and Mr. O'Reilly

Absent: Ms. Hemendinger, Dr. Jackson, Dr. Li, Dr. Mehta,

Investigators Submitting Applications for Review: Dr. Oldham

Guests: K. Brilliant (Brown University IACUC)

Support Staff: Ms. Poore

---

Note: Unless otherwise stated all motions were unanimously approved for 3 years.

After determining that quorum was met, Dr. Jayasuriya convened the meeting at 12:06 p.m.  
The following voting members were present when the meeting began: Dr. Jayasuriya, Dr.  
Dubielecka-Szczerba, Dr. Gregory, Mr. McEvoy, Dr. Merley, and Mr. O'Reilly

**Welcome and Opening Remarks:** The IBC chair read the COI statement aloud to remind members it is their responsibility to identify if they have a conflict of interest and to recuse themselves from review of that item.

**1 Review of Previous Minutes**  
**Minutes from 9/8/25**

Committee Action: The minutes were approved as submitted.

Vote: Number of members present 6, Approved 6, Opposed 0, Abstained 0, Recused 0

**2 Start of Hazard Business**

**3 New Studies Hazard**  
**3.1 [2370268-1] Doxycycline**

**PI:** William Oldham  
**Reference Number:** 503325  
**Submission Type:** New Project  
**Review Type:** Full Committee Review

Discussion:

- Dr. Oldham explained that doxycycline is used to regulate transgene expression in mice.
- Dr. Dubielecka noted that a hood must be used when handling this agent to reduce aerosol exposure.
- IBC application, item B5, check YES and provide details regarding the type of

hood that will be used.

- Dr. Dubielecka noted that Doxycycline will be administered in the drinking water. Accordingly, residual water left over when cages are changed must be collected, labeled, and disposed as chemical waste.
- Doxycycline is excreted unchanged in urine for 48 hours post-exposure and cages are considered to be hazardous for 72 hours post-exposure. Disposable caging must be used to reduce exposure to animal care staff.
- Item 14d, revise the response to reflect handling precautions of cages and residual drinking water and the use of disposable cages.
- Animal cages may be returned to standard housing 72 hours after doxycycline drinking water treatment has ended.
- Agent specific training will be completed with the IBC Vice Chair

Committee Action: The committee voted to require modifications to secure approval. Dr. Dubielecka will serve as designated reviewer for the response.

Vote: Number of members present 6 Approved 6 Opposed 0 Abstained 0 Recused 0

### 3.2 [2365681-1] Bleomycin

**PI:** William Oldham  
**Reference Number:** 503125  
**Submission Type:** New Project  
**Review Type:** Full Committee Review

#### Discussion:

- Dr. Oldham explained that bleomycin is commonly used in a model to induce lung fibrosis in animals.
- Double containment is required when transporting that agent.
- IBC application, item B6, expand transport details to include double containment (as was described for doxycycline above)
- Item 14b, expand the response to indicate that bleomycin is excreted unchanged in the urine
- As discussed for doxycycline, cages are considered to be hazardous for 72 hours post-exposure. Disposable caging must be used to reduce exposure to animal care staff.
- Item 14c, because bleomycin excreted largely unchanged, its unchanged form, not its metabolites represents a hazard to animals.
- Item 14d, revise the response to reflect handling precautions of cages and the use of disposable cages.
- Animal cages may be returned to standard housing 72 hours after bleomycin treatment has ended.
- Agent specific training will be completed with the IBC Vice Chair

Committee Action: The committee voted to require modifications to secure approval. Dr. Dubielecka will serve as designated reviewer for the response.

Vote: Number of members present 6 Approved 6 Opposed 0 Abstained 0 Recused 0

3.3 **[2370280-1] Kanamycin**

**PI:** William Oldham  
**Reference Number:** 503525  
**Submission Type:** New Project  
**Review Type:** Full Committee Review

Discussion: As this agent will not be used in animals and is not on the list of common lab agents which require review, no further review is required.

Committee Action: The committee acknowledged this application.

3.4 **[2370272-1] Histamine**

**PI:** William Oldham  
**Reference Number:** 503425  
**Submission Type:** New Project  
**Review Type:** Full Committee Review

Discussion: As this agent will not be used in animals and is not on the list of common lab agents which require review, no further review is required.

Committee Action: The committee acknowledged this application.

3.5 **[2370247-1] Chloramphenicol**

**PI:** William Oldham  
**Reference Number:** 503225  
**Submission Type:** New Project  
**Review Type:** Full Committee Review

Discussion: As this agent will not be used in animals and is not on the list of common lab agents which require review, no further review is required.

Committee Action: The committee acknowledged this application.

4 **Expedited and Revision Reviews Hazard**

5 **Administrative Reviews Hazard**

6 **Other Business Hazard**

7 **Start of DNA business**

8 **New Studies DNA**

9 **Continuing Reviews DNA**

10 **Revisions- Full Board DNA**

11 **Administrative Check-In**

11.1 **[1051242-19] Generation of stable progenitor stem cell line**

<b>PI:</b>	Chathuraka Jayasuriya, PhD	
<b>Reference Number:</b>	502317 lentivirus, retrovirus, adenovirus	
<b>Sponsor:</b>	OREF-MTF and NIH	
<b>Submission Type:</b>	Continuing Review/Progress Report	
<b>Review Type:</b>	Administrative Review	
<b>Action:</b>	Acknowledged	
<b>Effective Date:</b>	September 8, 2025	<b>Project Status:</b> Active
<b>Project Expiration:</b>	October 1, 2026	

11.2 **[1959725-9] Therapy of Carcinoma - lentivirus BSC**

<b>PI:</b>	Suzanne de la Monte, MD,MPH	
<b>Reference Number:</b>	504622 Lentivirus	
<b>Sponsor:</b>	Internal Funding	
<b>Submission Type:</b>	Continuing Review/Progress Report	
<b>Review Type:</b>	Administrative Review	
<b>Action:</b>	Acknowledged	
<b>Effective Date:</b>	September 26, 2025	
<b>Project Status:</b>	Active	
<b>Project Expiration:</b>	November 5, 2026	

12 **Expedited and Revision Reviews DNA**

13 **Administrative Reviews DNA**

14 **Exempt DNA**

15 **Other Business DNA**

15.1 **News from the NIH Office of Science Policy**

Discussion: The notice was briefly reviewed. No action is required at this time.

15.2 **Annual lab inspections**

Discussion: Annual BL-2 lab inspections are due and several members volunteered to complete the inspections.

## **16 End of DNA Business**

The meeting adjourned at 1:25 p.m.